Analyst Conference Summary

biotechnology

conference date: March 12, 2026 @ 2:00 PM PT
for quarter ending: December 12, 2026 (fourth quarter, Q4)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was $0, flat sequentially and flat from year-earlier.

GAAP Net Income was negative $ million, up sequentially from negative $41.4 million, and up from negative $ million year-earlier.

GAAP EPS was negative $, up sequentially from negative $0.19, and up from negative $ year-earlier.

Guidance:

Conference Highlights:

David Chang, CEO said ""

Cema-Cel (ALLO-501 or cemacabtagene ansegedleucel) for large B cell lymphona (LBCL) began a pivotal Phase 2 study, Alpha3, in June 2024, for first line treatment for patients likely to relaspse following immunotherapy. Enrollment completion expected 1H 2026. Futility analysis (comparing MRD conversion between the two arms comparing cema-cel after standard fludarabine and cyclophosphamide (FC) lymphodepletion versus observation) expected in 1H 2026. Cema-Cel is an allogeneic cell therapy. PFS primary endpoint. Believes the market opportunity has expanded to more than $9.5 billion. Could make a BLA submission in 2027. Developed a test for MRD (minimal residual disease), which would predict patients likely to relapse after RCHOP treatment. Over 250 patients had been tested for MRD by May 2025. But noted despite interest from additional sites there is competition to get patients for this trial. In Q2 2025 began expansion of trial sites to outside the U.S.

ALLO-329 for autoimmune disease started Phase 1 trial for rheumatology indications began in Q2 2025. Resolution is a basket trial across several autoimmune conditions including lupus, systemic sclerosis, and idiopathic inflammatory myopathies. Targets both CD19 and CD70. Has Dagger technology to eliminate lymphodepletion. Believes differentiated from competitors.

ALLO-316 is a Phase 1b trial (Traverse) for advanced Renal Cell Carcinoma and completed enrolling the cohort. Latest data released mid-2025 at ASCO is promising. Then met with FDA on pivotal trial design. Could pursue a strategic partnership for this potential therapy.

Allogene also has ALLO-213 and ALLO-182 for solid tumors in preclinical development.

Total operating expenses (GAAP) were $ million, consisting of: R&D $ million; G&A $ million; impairment $0 million. Loss from operations was $ million. Other income net $ million. Income tax $0 million.

Cash and equivalents ended at $ million, down sequentially from $277 million.

Q&A selective summary:

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: